Nutriband Past Earnings Performance

Past criteria checks 0/6

Nutriband's earnings have been declining at an average annual rate of -20.8%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 30.7% per year.

Key information

-20.8%

Earnings growth rate

-14.6%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate30.7%
Return on equity-61.0%
Net Margin-338.7%
Last Earnings Update31 Oct 2024

Recent past performance updates

Recent updates

Is Nutriband (NASDAQ:NTRB) A Risky Investment?

Mar 31
Is Nutriband (NASDAQ:NTRB) A Risky Investment?

Is Nutriband (NASDAQ:NTRB) Weighed On By Its Debt Load?

Sep 13
Is Nutriband (NASDAQ:NTRB) Weighed On By Its Debt Load?

Nutriband GAAP EPS of -$0.12, revenue of $0.5M

Sep 08

Nutriband opens a new branch in Ecuador with plans to expand into the South American market

Jul 22

Nutriband: Advancing Transdermal Delivery Of Injectable Drugs

Nov 01

Does Nutriband (NASDAQ:NTRB) Have A Healthy Balance Sheet?

Oct 06
Does Nutriband (NASDAQ:NTRB) Have A Healthy Balance Sheet?

Revenue & Expenses Breakdown

How Nutriband makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:NTRB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Oct 242-733
30 Apr 242-643
31 Jan 242-542
31 Oct 232-542
31 Jul 232-541
30 Apr 232-541
31 Jan 232-441
31 Oct 222-741
31 Jul 222-751
30 Apr 221-741
31 Jan 221-640
31 Oct 211-550
31 Jul 211-340
30 Apr 211-330
31 Jan 211-330
31 Oct 201-210
31 Jul 200-210
30 Apr 200-310
31 Jan 200-320
31 Oct 190-220
31 Jul 191-220
30 Apr 190-330
31 Jan 190-330
31 Oct 180-530
31 Jul 180-520
30 Apr 180-310
31 Jan 180-300
31 Oct 170000
31 Jul 170000
30 Apr 170000
31 Jan 170000

Quality Earnings: NTRB is currently unprofitable.

Growing Profit Margin: NTRB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NTRB is unprofitable, and losses have increased over the past 5 years at a rate of 20.8% per year.

Accelerating Growth: Unable to compare NTRB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NTRB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: NTRB has a negative Return on Equity (-60.96%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 09:22
End of Day Share Price 2024/12/23 00:00
Earnings2024/10/31
Annual Earnings2024/01/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nutriband Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eric BederSmall Cap Consumer Research LLC
Marla MarinZacks Small-Cap Research